Below are the most recent publications written about "Receptors, Androgen" by people in Profiles.
-
Chahdi A, Jorgez C, Rosenfeld JA, Neetu N, Seth A. Androgen receptor ubiquitination links KCTD13 to genitourinary tract defects. FASEB J. 2025 Feb 28; 39(4):e70406.
-
Jorgez CJ, Chahdi A, Flores H, O'Neill M, Seth A. Role of Kctd13 in modulating AR and SOX9 expression in different penile cell populations. Andrology. 2025 07; 13(5):1201-1212.
-
Karliner J, Liu Y, Merry DE. Mutant androgen receptor induces neurite loss and senescence independently of ARE binding in a neuronal model of SBMA. Proc Natl Acad Sci U S A. 2024 07 16; 121(29):e2321408121.
-
Karan D, Dubey S, Gunewardena S, Iczkowski KA, Singh M, Liu P, Poletti A, Choo YM, Chen HZ, Hamann MT. Manzamine A reduces androgen receptor transcription and synthesis by blocking E2F8-DNA interactions and effectively inhibits prostate tumor growth in mice. Mol Oncol. 2024 08; 18(8):1966-1979.
-
Lisberg A, Liu Y, Merry DE. Blocking the dimerization of polyglutamine-expanded androgen receptor protects cells from DHT-induced toxicity by increasing AR turnover. J Biol Chem. 2024 05; 300(5):107246.
-
McKay RR, Morgans AK, Shore ND, Dunshee C, Devgan G, Agarwal N. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States. Cancer Treat Rev. 2024 May; 126:102726.
-
Maranto C, Sabharwal L, Udhane V, Pitzen SP, McCluskey B, Qi S, O'Connor C, Devi S, Johnson S, Jacobsohn K, Banerjee A, Iczkowski KA, Wang L, Dehm SM, Nevalainen MT. Stat5 induces androgen receptor (AR) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling. Sci Adv. 2024 03; 10(9):eadi2742.
-
Chahdi A, Jorgez C, Seth A. Regulation of androgen receptor stability by the ?1 Pix/STUB1 complex. FASEB J. 2024 02; 38(2):e23408.
-
Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song WM, Fujiwara N, Li P, Mendizabal I, Petrylak DP, Kelly WK, Reddy EP, Wang L, Schiewer MJ, Lujambio A, Karnes J, Knudsen KE, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer. Cancer Discov. 2023 12 12; 13(12):2584-2609.
-
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zsch?bitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023 07 22; 402(10398):291-303.